Evidence map›Paper›PMID 36322624›Full record

ArticleNeuro-oncology2023

ARL13B promotes angiogenesis and glioma growth by activating VEGFA-VEGFR2 signaling.

Limin Chen, Xinsheng Xie, Tiantian Wang, Linlin Xu, Zhenyu Zhai, Haibin Wu, Libin Deng, Quqin Lu, Zhengjun Chen, Xiao Yang and 3 more

Abstract read
In one paragraph

Article in Neuro-oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed.

  1. Article
  2. Role of ZEB1 in angiogenesis and therapeutic potential (Review).International journal of molecular medicine · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Limin ChenCenter for Experimental Medicine, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Xinsheng XieCenter for Experimental Medicine, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Tiantian WangCenter for Experimental Medicine, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Linlin XuCenter for Experimental Medicine, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Zhenyu ZhaiCenter for Experimental Medicine, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Haibin WuCenter for Experimental Medicine, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Libin DengDepartment of Epidemiology and Biostatistics, School of Public Health, Nanchang University, Nanchang, China.
Quqin LuDepartment of Epidemiology and Biostatistics, School of Public Health, Nanchang University, Nanchang, China.
Zhengjun ChenCenter for Excellence in Molecular Cell Science, Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, Shanghai, China.
Xiao YangGenetic Laboratory of Development and Disease, Institute of Lifeomics, National Center for Protein Sciences, Beijing, China.ORCID 0000-0002-0298-9831
Hua LuDepartment of Biochemistry and Molecular Biology, Tulane University School of Medicine, New Orleans, USA.
Ye-Guang ChenSchool of Life Sciences, Tsinghua University, Beijing, China.
Shiwen LuoCenter for Experimental Medicine, The First Affiliated Hospital of Nanchang University, Nanchang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTumor angiogenesis is essential for solid tumor progression, invasion and metastasis. The aim of this study was to identify potential signaling pathways involved in tumor angiogenesis.

methodsGenetically engineered mouse models were used to investigate the effects of endothelial ARL13B(ADP-ribosylation factor-like GTPase 13B) over-expression and deficiency on retinal and cerebral vasculature. An intracranially transplanted glioma model and a subcutaneously implanted melanoma model were employed to examine the effects of ARL13B on tumor growth and angiogenesis. Immunohistochemistry was used to measure ARL13B in glioma tissues, and scRNA-seq was used to analyze glioma and endothelial ARL13B expression. GST-fusion protein-protein interaction and co-immunoprecipitation assays were used to determine the ARL13B-VEGFR2 interaction. Immunobloting, qPCR, dual-luciferase reporter assay and functional experiments were performed to evaluate the effects of ARL13B on VEGFR2 activation.

resultsEndothelial ARL13B regulated vascular development of both the retina and brain in mice. Also, ARL13B in endothelial cells regulated the growth of intracranially transplanted glioma cells and subcutaneously implanted melanoma cells by controlling tumor angiogenesis. Interestingly, this effect was attributed to ARL13B interaction with VEGFR2, through which ARL13B regulated the membrane and ciliary localization of VEGFR2 and consequently activated its downstream signaling in endothelial cells. Consistent with its oncogenic role, ARL13B was highly expressed in human gliomas, which was well correlated with the poor prognosis of glioma patients. Remarkably, ARL13B, transcriptionally regulated by ZEB1, enhanced the expression of VEGFA by activating Hedgehog signaling in glioma cells.

conclusionsARL13B promotes angiogenesis and tumor growth by activating VEGFA-VEGFR2 signaling. Thus, targeting ARL13B might serve as a potential approach for developing an anti-glioma or anti-melanoma therapy.

Indexed as

Endothelial CellsGliomaADP-Ribosylation FactorsAnimalsCell ProliferationHedgehog ProteinsHumansMiceNeovascularization, PathologicSignal TransductionVascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-2ADP-Ribosylation FactorsARL13B protein, humanArl13b protein, mouseHedgehog ProteinsVascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-2VEGFA protein, humanARL13Bintercellular communicationtumor angiogenesisvascular developmentVEGFR2

Identifiers

PMID36322624
PMCPMC10158193

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.